The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.50 per share for the second quarter of 2025. The dividend will be paid on Tuesday, June 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Monday, April 21, 2025.

Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA). This supplement includes updated labeling based on post-approval experience with Librela in the U.S. since the product launched over a year ago. The company remains confident in the safety and effectiveness of Librela and plans to implement the updated label immediately in its ongoing commitment to supporting veterinarians and pet owners in the use of Librela. The revised label can be found by clicking here.

These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the call.

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21, 2025.

Zoetis Inc. (NYSEZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET.

Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.

Zoetis Inc. (NYSEZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities.

Zoetis Inc. (NYSEZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT.

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president.

ZTS earnings call for the period ending September 30, 2024.

Zoetis stock inched higher Monday after the animal health company beat third-quarter expectations and raised its outlook.

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday.

Zoetis Inc's Q3 2024 results show a 16% EPS increase and an 11% revenue boost. The company raises its 2024 guidance, highlighting strong global growth in key segments.